The Cancer Strategy Taskforce has published a report setting out how to transform cancer services in England.
Click here to view the report.
Responding to the report, Alison Clough, acting CEO of the ABPI, said: “ It is vital that we improve cancer outcomes for UK patients where we still lag behind other countries. An important part of this is earlier diagnosis, but we also need to ensure that once patients are diagnosed they have access to the latest treatments.
“The UK remains low and slow compared to other countries when it comes to accessing new, innovative medicines, including those for cancer. As the report recognises, we urgently need a long-term solution that ensures that cancer patients have earlier access to new medicines. The ABPI continues to work with the NHS, clinicians and charities to remove the barriers all patients face in getting access to life-changing treatments.
“We see the current Accelerated Access Review, aimed at improving patient outcomes, as one way of making progress in this area.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com